Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies

Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies

Abstract Background Surgical procedures impose hemostatic risk to people with hemophilia, which may be minimized by optimal factor (F) replacement therapy. Methods This analysis evaluates the efficacy and safety of extended half‐life factor replacement recombinant FVIII and FIX Fc fusion proteins (r...

Full description

Bibliographic Details
Main Authors: Pratima Chowdary, Margareta Holmström, Johnny N. Mahlangu, Margaret C. Ozelo, Ingrid Pabinger, K. John Pasi, Margaret V. Ragni, Amy Shapiro, Chris Barnowski, Stefan Lethagen
Format: Article
Language:English
Published: Elsevier 2022-07-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
factor IX fc fusion protein
factor VIII Fc fusion protein
hemophilia A
hemophilia B
recombinant fusion proteins
safety
Online Access:https://doi.org/10.1002/rth2.12760

Internet

https://doi.org/10.1002/rth2.12760

Similar Items